

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (Previously Presented) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of hyaluronic acid in crosslinked form.

2. (Previously Presented) A method according to claim 1, wherein administering is by local administration.

3. (Previously Presented) A method according to claim 1, wherein administering is to the border of the dermoepithelial transition.

4. (Previously Presented) A method according to claim 1, wherein the degree of crosslinking is 0.1% to 10%.

5. (Currently Amended) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of a mixture comprising crosslinked and A method according to claim 1, wherein the crosslinked hyaluronic acid is present in a mixture with uncrosslinked hyaluronic acid.

6. (Previously Presented) A method according to claim 5, wherein the uncrosslinked hyaluronic acid is

(i) long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD, or

(ii) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD, or

(iii) a mixture thereof.

7. (Withdrawn) A method according to claim 1, wherein the hyaluronic acid is in a composition which contains an inhibitor of hyaluronic acid degradation.

8. (Withdrawn) A method according to claim 7, wherein the inhibitor of hyaluronic acid degradation is heparin, indomethacin, a salicylate, a free radical trap, or vitamin A, C or E, or a mixture thereof.

9. (Previously Presented) A method according to claim 1, wherein the hyaluronic acid is present as an injectable preparation.

10. (Withdrawn) A method according to claim 1, wherein the hyaluronic acid is in a composition which contains a further glycosaminoglycan in crosslinked or uncrosslinked form.

11. (Previously Presented) A method according to claim 1, wherein the inflammatory skin or mucous membrane disease is atopic dermatitis, eczema, seborrheic or microbial eczema, pruritus, prurigo, urticaria, red lichen, psoriasis, psoriasis vulgaris, vitiligo, a viral skin disease which leads to wart formation, verruca vulgaris, Condylomata accuminata, rosacea, perioral dermatitis, acne, acne vulgaris, acne conglobata, a polypous mucous membrane disease, nasal polyposis, an inflammatory intestinal disease, a chronic or acute ulceration of the skin, aphthae or mycoses.

12. (Previously Presented) A method according to claim 1, wherein the subject is a human.

13. (Previously Presented) A method according to claim 1, wherein the subject is a veterinary patient.

14-21. (Cancelled)

22. (Withdrawn) A method according to claim 1, wherein the inflammatory skin or mucous membrane disease is atopic dermatitis.

23. (Previously Presented) A method according to claim 1, wherein the inflammatory skin or mucous membrane disease is a viral skin disease which leads to wart

formation.

24. (Withdrawn) A method according to claim 1, wherein the inflammatory skin or mucous membrane disease is acne vulgaris.

25. (New) A method for treating an inflammatory skin or mucous membrane disease, comprising administering intradermally to a subject in need thereof an effective amount of a mixture comprising crosslinked and uncrosslinked hyaluronic acid, wherein the uncrosslinked hyaluronic acid is

(a) short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD, or

(b) a mixture of long-chain hyaluronic acid having an average molecular weight (weight-average) of at least 200 kD, and short-chain hyaluronic acid having an average molecular weight (weight-average) up to 50 kD.

26. (New) A method according to claim 1, wherein the administered hyaluronic acid is not administered in conjunction with a penetration-promoting agent.